Evidence mapPaperPMID 42174604Full record

ReviewJournal of translational medicine2026

Reframing ME/CFS: toward a unified mechanistic model of chronic post-infectious diseases.

Paul Watton, Bhupesh K Prusty

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Paul WattonIndependent Scientist, Overton Lodge, Coach Road, Overton, Nr. Ashover, Chesterfield, Derbyshire, S45 0JN, UK.
Bhupesh K PrustyInstitute of Microbiology and Virology, Riga Stradiņš University, Ratsupites iela 5, Riga, LV-1067, Latvia. bhupesh.prusty@rsu.lv.ORCID http://orcid.org/0000-0001-7051-4670

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multisystem illness marked by post-exertional malaise (PEM), cognitive dysfunction, autonomic disturbance, and impaired physiological resilience. Historically, the absence of validated biomarkers, heterogeneous definitions, and limited investigative capacity have complicated mechanistic interpretation and contributed to the use of psychosocial and rehabilitative frameworks in clinical practice and in parts of the literature. MAIN BODY: Advances in systems biology, accelerated by Long-COVID research, have transformed our understanding of post-infectious syndromes, implicating persistent immune dysregulation, mitochondrial and metabolic reprogramming, endothelial and microvascular dysfunction, abnormal coagulation, lipid-mediated signalling, extracellular vesicle communication, and viral protein-associated immune activation. This review charts the shift from early post-infectious observations through psychosocial dominance to contemporary biological frameworks, emphasising that pathology is state-dependent and revealed under physiological stress.

conclusionME/CFS is thus reframed here as a disorder of impaired adaptive capacity within post-infectious disease biology.

Indexed as

Fatigue Syndrome, ChronicModels, BiologicalChronic DiseaseHumansMitochondriaPost-Infectious DisordersImmune dysregulationImpaired physiological resilienceMitochondrial and metabolic reprogrammingPost-Exertional Malaise (PEM)Post-infectious disease biology

Identifiers

PMID42174604
PMCPMC13288801

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.